ERBB2 and breast cancer: In 2019, based on the results of the DESTINY-Breast01 trial, the FDA granted accelerated approval to T-Dxd in metastatic or unresectable HER2-positive breast cancer patients previously treated with at least two anti-HER2-based regimens [43].